Osteoporosis patients may benefit from treatments targeting NOX4 activity

Date: Oct-17-2013Bone is constantly being broken down and remodeled. Osteoporosis results when bone resorption outpaces bone regeneration. Production of reactive oxygen species, a form of oxidative stress, has been predicted to promote bone loss, but a source of reactive oxygen is unknown.

In this issue of the Journal of Clinical Investigation, Katrin Schröder and colleagues at Goethe-University identify a relationship between NADPH oxidase 4 (NOX4), an enzyme that promotes reactive oxygen species formation, and bone resorption.

In a mouse model of osteoporosis, genetic disruption or drug-induced loss of NOX4 protected the mice from bone loss. Additionally, the authors identify a small nuclear polymorphism in NOX4 in human patients that associated with increased bone turnover.

Together, these data suggest treatments targeting NOX4 activity may benefit osteoporosis patients.

TITLE: NADPH oxidase 4 limits bone mass by promoting osteoclastogenesis

Courtesy: Medical News Today Note: Any medical information available in this news section is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional.